EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieOpen Access

Quality-of-life outcomes and risk prediction for patients randomized to nivolumab plus ipilimumab vs nivolumab on LungMAP-S1400I

Joseph M Unger iD, Lu Qian, Mary W Redman, Susan S Tavernier, Lori Minasian, Ellen V Sigal, Vassiliki A Papadimitrakopoulou, Michael Leblanc, Charles S Cleeland, Samuel A Dzingle, Thomas J Summers, Herta Chao und 10 weitere

JNCI: Journal of the National Cancer Institute · 2023

DOI: 10.1093/jnci/djad003 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift JNCI: Journal of the National Cancer Institute, 2023. Verfasst von Joseph M Unger und 21 weiteren Autor:innen. Beteiligte Einrichtung: SWOG Statistics and Data Management Center, Seattle, WA, USA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, NCI NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

An important issue for patients with cancer treated with novel therapeutics is how they weigh the effects of treatment on survival and quality of life (QOL). We compared QOL in patients enrolled to SWOG S1400I, a substudy of the LungMAP biomarker-driven master protocol.

Methods

SWOG S1400I was a randomized phase III trial comparing nivolumab plus ipilimumab vs nivolumab for treatment of immunotherapy-naïve disease in advanced squamous cell lung cancer. The primary endpoint was the MD Anderson Symptom Inventory–Lung Cancer severity score at week 7 and week 13 with a target difference of 1.0 points, assessed using multivariable linear regression. A composite risk model for progression-free and overall survival was derived using best-subset selection.

Results

Among 158 evaluable patients, median age was 67.6 years and most were male (66.5%). The adjusted MD Anderson Symptom Inventory–Lung Cancer severity score was 0.04 points (95% confidence interval [CI] = −0.44 to 0.51 points; P = .89) at week 7 and 0.12 points (95% CI = −0.41 to 0.65; P = .66) at week 13. A composite risk model showed that patients with high levels of appetite loss and shortness of breath had a threefold increased risk of progression or death (hazard ratio [HR] = 3.06, 95% CI = 1.88 to 4.98; P < .001) and that those with high levels of both appetite loss and work limitations had a fivefold increased risk of death (HR = 5.60, 95% CI = 3.27 to 9.57; P < .001)—compared with those with neither risk category.

Conclusions

We found no evidence of a benefit of ipilimumab added to nivolumab compared with nivolumab alone for QOL in S1400I. A risk model identified patients at high risk of poor survival, demonstrating the prognostic relevance of baseline patient-reported outcomes even in those with previously treated advanced cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsHumansMaleAgedFemaleNivolumabIpilimumabQuality of LifeAntineoplastic Combined Chemotherapy Protocols

Substanzen

NivolumabIpilimumab

Autor:innen und Institutionen

  • SWOG Statistics and Data Management Center, Seattle, WA, USA.
  • Fred Hutchinson Cancer Center, Seattle, WA, USA.
  • Idaho State University, Pocatello, ID, USA.
  • Division of Cancer Prevention, National Cancer Institute, Community Oncology and Prevention Trials Group, Rockville, MD, USA.
  • Friends of Cancer Research, Washington, DC, USA.
  • The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

ORCID-Profile: Joseph M Unger

Förderung

  • NCATS NIH HHS
  • NCI NIH HHS
  • National Institutes of Health
  • NCI

Zitieren

APA

Unger, J. M., Qian, L., Redman, M. W., Tavernier, S. S., Minasian, L., Sigal, E. V., Papadimitrakopoulou, V. A., Leblanc, M., Cleeland, C. S., Dzingle, S. A., Summers, T. J., Chao, H., Madhusudhana, S., Villaruz, L., Crawford, J., Gray, J. E., Kelly, K. L., Gandara, D. R., Bazhenova, L., …, & Moinpour, C. M. (2023). Quality-of-life outcomes and risk prediction for patients randomized to nivolumab plus ipilimumab vs nivolumab on LungMAP-S1400I. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djad003

Vancouver

Unger JM, Qian L, Redman MW, Tavernier SS, Minasian L, Sigal EV, et al. Quality-of-life outcomes and risk prediction for patients randomized to nivolumab plus ipilimumab vs nivolumab on LungMAP-S1400I. JNCI: Journal of the National Cancer Institute. 2023. doi:10.1093/jnci/djad003

BibTeX
@article{Unger2023,
  author = {Unger, Joseph M and Qian, Lu and Redman, Mary W and Tavernier, Susan S and Minasian, Lori and Sigal, Ellen V and Papadimitrakopoulou, Vassiliki A and Leblanc, Michael and Cleeland, Charles S and Dzingle, Samuel A and Summers, Thomas J and Chao, Herta and Madhusudhana, Sheshadri and Villaruz, Liza and Crawford, Jeffrey and Gray, Jhanelle E and Kelly, Karen L and Gandara, David R and Bazhenova, Lyudmila and Herbst, Roy S and Gettinger, Scott N and Moinpour, Carol M},
  title = {Quality-of-life outcomes and risk prediction for patients randomized to nivolumab plus ipilimumab vs nivolumab on LungMAP-S1400I},
  journal = {JNCI: Journal of the National Cancer Institute},
  year = {2023},
  doi = {10.1093/jnci/djad003}
}
Kostenlos starten →